The range of therapeutic options in prostate cancer is expanding, including strategies for PARP inhibition. The aim of this e-learning course is to provide an understanding of the mechanism of action of PARP inhibitors; the prevalence of DNA damage repair (DDR) mutations in advanced prostate cancer, as well as approaches for somatic and germline testing to identify patients with these mutations; and the recent and ongoing clinical trial data on PARP inhibition in advanced prostate cancer. Watch this video from Dr. Neal D. Shore and download the educational slides to learn more. Follow the link below to start your e-learning journey today.
This course has been developed by the following expert faculty:
- Dr. Neal D. Shore, Carolina Urologic Research Center (Myrtle Beach, South Carolina, USA)
- Prof. Andrew J. Armstrong, Duke University School of Medicine (Durham, North Carolina, USA)
- Prof. Emmanuel S. Antonarakis, Johns Hopkins Medicine (Baltimore, Maryland, USA)